• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
WANG Sijie,LIU Qin,HE Wenzhi,SHEN Xue,YANG Huan,WU Fan,FEI Chengrui.Practice on improving biological product testing capability in Yunnan's biomedicine development[J].Journal Of Pharmaceutical Research,2026,45(9):1018-1023,1039[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 228times   Download 200次 QR Code for this article
Scan with your phone!
云南生物医药发展下生物制品检验能力提升实践
王思捷,刘勤,和文志,申雪,杨欢,吴凡,非成瑞
Font:Larger+|Default|Smaller-
(云南省食品药品监督检验研究院,工业和信息化部产业技术基础公共服务平台,云南 昆明 650106)
摘要:
目的 为省级药检机构提升生物制品检验能力提供参考。方法 结合云南省生物医药产业发展,分析产业升级对药检能力与监管提出的新要求,并基于云南院2019—2025年以疫苗批签发为核心的检验能力建设实践,从人员、设备、样品、体系、环境及生物安全等方面系统阐述建设路径与优化建议。结果与结论 云南院以批签发能力建设为突破口,通过“品种+设备”双负责人等创新机制,快速构建起覆盖主要品种的完整检验体系,有力支撑了属地监管与产业创新。其经验表明,需求导向、项目驱动、政策支持与持续投入相结合,是省级药检机构补齐短板、服务产业高质量发展的有效路径。
关键词:  生物制品  检验能力建设  质量管理体系
DOI:10.13506/j.cnki.jpr.2026.09.009
基金项目:云南省科技厅重大科技专项计划项目(No.202002AA100008)
Received Date:May 06, 2026   Revision Date:June 10, 2026   Publication Date:September 30, 2026
Practice on improving biological product testing capability in Yunnan's biomedicine development
WANG Sijie,LIU Qin,HE Wenzhi,SHEN Xue,YANG Huan,WU Fan,FEI Chengrui
(Ministry of Industry and Information Technology Industrial Technology Infrastructure Public Service Platform,Yunnan Institute of Supervision and Inspection for Food and Drug,Kunming 650106,China)
Abstract:
Objective To provide a reference for provincial drug testing institutions to enhance their biological product testing capabilities. Methods This paper based on the development of Yunnan Province's biopharmaceutical industry, analyzes the new requirements for drug testing capabilities and supervision brought by industrial upgrading. It systematically details the construction path and optimization suggestions across personnel, equipment, samples, quality systems, environment, and biosafety, drawing on the Yunnan Institute of Supervision and Inspection for Food and Drug's practice in building testing capabilities centered on vaccine batch release from 2019 to 2025. Results and Conclusion Through measures like a "variety + equipment" dual-responsible person system, the Yunnan Institute quickly established a comprehensive testing system covering major product categories, using batch release capacity as a breakthrough.. This has strongly supported local supervision and industrial innovation. Its experience indicates that demand orientation, a project-driven approach, policy support, and sustained investment form an effective path for provincial drug testing institutions to address gaps and support high-quality industry development.
Key words:  Biological products  Inspection capacity building  Quality management system
Today's Visits:447    Total Visits:2383131
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.